UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer
Pursuant to Rule 13A-16
or 15d-16 of
The
Securities Exchange Act of 1934
For
the month of July 2017
COMMISSION
FILE Number.
000-29338
CARDIOME
PHARMA CORP.
(Translation
of registrant’s name into English)
1441
Creekside Drive, 6th floor
Vancouver,
British Columbia, V6J 4S7, CANADA
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
DOCUMENTS INCLUDED AS PART OF THIS REPORT
Exhibit |
|
Description |
|
|
|
99.1 |
|
News Release dated July 3, 2017 - Cardiome's Partner SteadyMed Submits U.S. New Drug Application for TREVYENT® for the Treatment of Pulmonary
Arterial Hypertension |
|
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
CARDIOME
PHARMA CORP. |
|
(Registrant) |
|
|
|
Date: July 3, 2017 |
By: |
/s/
Justin Renz |
|
|
Name: Justin Renz |
|
|
Title: Chief Financial Officer |
Exhibit 99.1
Cardiome's Partner SteadyMed Submits U.S. New Drug Application
for TREVYENT® for the Treatment of Pulmonary Arterial Hypertension
NASDAQ:CRME TSX:COM
VANCOUVER, July 3, 2017 /CNW/ - Cardiome Pharma Corp. (NASDAQ:CRME
/ TSX:COM) today announced that partner SteadyMed Ltd (NASDAQ:STDY) submitted a New Drug Application (NDA) to the U.S. Food and
Drug Administration (FDA) for TREVYENT® (treprostinil injection). TREVYENT® is a drug-device combination
product that utilizes SteadyMed's PatchPump® technology to deliver treprostinil, a vasodilatory prostacyclin analogue,
for the treatment of pulmonary arterial hypertension (PAH).
PatchPump® is a proprietary, disposable, parenteral
drug administration platform that is prefilled and preprogrammed at the site of manufacture. Cardiome licensed the commercial rights
to TREVYENT® for many international markets in June 2015. Cardiome expects to file TREVYENT® for
European Medicines Agency (EMA) and Health Canada approval by the end of 2017.
"The NDA filing with the FDA is an important step in
the development of TREVYENT®, and advances us closer to our goal of bringing what we believe is a better way to
deliver treprostinil to patients around the world who are suffering from PAH," said Hugues Sachot, Cardiome's Chief Commercial
Officer. "Our partnership with SteadyMed continues to progress well, and we will work closely with them to file with both
the EMA and Health Canada by the end of this year."
About Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries
that supply blood to the lungs. PAH worsens over time and is life-threatening because the pressure in a patient's pulmonary arteries
rises to dangerously high levels, putting a strain on the heart. There is no cure for PAH, but several medications are available
to treat symptoms, such as the market-leading prostacyclin PAH therapy, Remodulin® (treprostinil injection), which
is produced by United Therapeutics Corporation. The annual cost of Remodulin is reported to be between approximately $125,000 and
$175,000 per patient and United Therapeutics reported Remodulin revenues of $602 million in 2016.
About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a specialty pharmaceutical company dedicated to the development and commercialization of innovative therapies
that will improve the quality of life and health of patients suffering from disease. Cardiome has two marketed, in-hospital, cardiology
products, BRINAVESS® (vernakalant IV), approved in Europe, Canada, and other territories for the rapid conversion
of recent onset atrial fibrillation to sinus rhythm in adults, and AGGRASTAT® (tirofiban HCl) a reversible GP IIB/IIIa inhibitor
indicated for use in patients with acute coronary syndrome. Cardiome also commercializes ESMOCARD® and ESMOCARD LYO® (esmolol
hydrochloride), a short-acting beta-blocker used to control rapid heart rate in a number of cardiovascular indications, on behalf
of their partner Amomed in select European markets. Cardiome has also licensed: XYDALBA™ (dalbavancin hydrochloride), a second
generation, semi-synthetic lipoglycopeptide approved in the EU for the treatment of acute bacterial skin and skin structure infections
(ABSSSI) in adults for select European and Middle Eastern nations and Canada from Allergan; and TREVYENT®, a development
stage drug device combination that is under development for Pulmonary Arterial Hypertension for Europe, the Middle East and for
Canadian markets from SteadyMed Therapeutics.
Cardiome is traded on the NASDAQ Capital Market (CRME) and
the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.
Forward Looking Disclaimer
Certain statements in this news release contain forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable
Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the
words "believe", "may", "plan", "will", "estimate", "continue", "anticipate",
"intend", "expect" and similar expressions. Forward-looking statements may involve, but are not limited to,
comments with respect to our objectives and priorities for 2017 and beyond, our strategies or future actions, our targets, expectations
for our financial condition and the results of, or outlook for, our operations, research and development and product and drug development.
Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results,
events or developments to be materially different from any future results, events or developments expressed or implied by such
forward-looking statements. Many such known risks, uncertainties and other factors are taken into account as part of our assumptions
underlying these forward-looking statements and include, among others, the following: general economic and business conditions
in the United States, Canada, Europe, and the other regions in which we operate; market demand; technological changes that could
impact our existing or future products; competition; existing governmental legislation and regulations and changes in, or the failure
to comply with, governmental legislation and regulations; availability of financial reimbursement coverage from governmental and
third-party payers for products and related treatments; adverse results or unexpected delays in pre-clinical and clinical product
development processes; adverse findings related to the safety and/or efficacy of our products or products; decisions, and the timing
of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial
funding to expand commercialization activities; and any other factors that may affect our performance. In addition, our business
is subject to certain operating risks that may cause any results expressed or implied by the forward-looking statements in this
presentation to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified
personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in our business
strategy or development plans; intellectual property matters, including the unenforceability or loss of patent protection resulting
from third-party challenges to our patents; market acceptance of our technology and products; our ability to successfully manufacture,
market and sell our products; the availability of capital to finance our activities. These and other risks are described
in the Form 40F and associated documents filed March 29, 2017 (see for example, "Risk Factors" in the Annual Information
Form for the year ended December 31, 2016), in the Form 6-K filed May 15, 2017, and in our other filings with the Securities and
Exchange Commission ("SEC") available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com.
Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements
and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information
made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements
and information to reflect subsequent events or circumstances, except as required by law.
SOURCE Cardiome Pharma Corp.
View original content: http://www.newswire.ca/en/releases/archive/July2017/03/c5429.html
%CIK: 0001036141
For further information: Justin Renz, Cardiome Investor Relations,
(604) 677-6905 ext. 128 or Toll Free: 1-800-330-9928, Email: jrenz@cardiome.com
CO: Cardiome Pharma Corp.
CNW 08:00e 03-JUL-17
This regulatory filing also includes additional resources:
ex991.pdf
Correvio Pharma (NASDAQ:CORV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Correvio Pharma (NASDAQ:CORV)
Historical Stock Chart
From Apr 2023 to Apr 2024